Back to resultsQ-Switched Nd:YAG in Macular Amyloidosis
Primary Purpose
Macular Amyloidosis
Status
Completed
Phase
Phase 1
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Laser Therapy
Sponsored by
About this trial
This is an interventional treatment trial for Macular Amyloidosis
Eligibility Criteria
Inclusion Criteria: Macular amyloidosis confirmed cases Exclusion Criteria: Pregnancy and breast feeding Over 18 years old
Sites / Locations
- Skin Research Center, Shaheed Beheshti Medical University
Outcomes
Primary Outcome Measures
Visual and colorimetric assessment
Secondary Outcome Measures
Full Information
NCT ID
NCT00353392
First Posted
July 17, 2006
Last Updated
December 18, 2013
Sponsor
Shahid Beheshti University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT00353392
Brief Title
Q-Switched Nd:YAG in Macular Amyloidosis
Study Type
Interventional
2. Study Status
Record Verification Date
November 2006
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
July 2006 (Actual)
Study Completion Date
August 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Shahid Beheshti University of Medical Sciences
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to determine whether Q-Switched Nd:YAG Laser therapy are effective in reduction of Cutaneous macular amyloidosis.
Detailed Description
We treat the macular amyloidosis cases by Q-Switched Nd:YAG Laser and compare the before and after treatment situation by the photos and colorimetric assessment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Macular Amyloidosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Single
Allocation
Randomized
Enrollment
20 (false)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Laser Therapy
Primary Outcome Measure Information:
Title
Visual and colorimetric assessment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Macular amyloidosis confirmed cases
Exclusion Criteria:
Pregnancy and breast feeding
Over 18 years old
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nima Ostovari, M.D.
Organizational Affiliation
Shahid Beheshti University of Medical Sciences
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Parviz Toossi, MD
Organizational Affiliation
Shaheed Beheshti Medica University
Official's Role
Study Chair
Facility Information:
Facility Name
Skin Research Center, Shaheed Beheshti Medical University
City
Tehran
ZIP/Postal Code
19899
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Learn more about this trial
Q-Switched Nd:YAG in Macular Amyloidosis
We'll reach out to this number within 24 hrs